Oxford Ledge
Search
Actuate Therapeutics Inc (NASDAQ: ACTU) is a biotechnology company trading at $2.03 (−1.0% today). Figures from SEC EDGAR and market feeds; updated 2026-07-14 13:01 UTC.
The company is a clinical-stage biopharmaceutical firm developing elraglusib, a small molecule GSK-3 inhibitor designed to treat difficult-to-treat cancers by blocking an enzyme involved in tumor cell survival and growth. Elraglusib is exclusively licensed from a collaboration between the University of Illinois-Chicago and Northwestern University, and the company has treated patients with the drug in clinical trials across multiple cancer types.
Summarized from Actuate Therapeutics Inc’s SEC filings · Read the filing ↗
| Quote | |
| Price | $2.03 |
| Change (1D) | -0.02 (-0.98%) |
| Volume | 52.9K shares |
| 52-week range | $1.58 – $9.22 |
| Returns | |
| 52-week return | +28.5% |
The company is a clinical-stage biopharmaceutical firm developing elraglusib, a small molecule GSK-3 inhibitor designed to treat difficult-to-treat cancers by blocking an enzyme involved in tumor cell survival and growth.
ACTU trades at $2.03, as of 2026-07-14.
Actuate Therapeutics Inc's most recent SEC filing on record is a 8-K filed 2026-05-22. All filings link to their SEC EDGAR originals above.
SEC EDGAR filings and public market data feeds, fetched 2026-07-14 13:01 UTC. This page is also available as JSON at /api/data?ticker=ACTU and is emitted with FAQPage structured data for machine reading.
Charts, 10-year financials, peer comparison, screening and portfolio tracking for ACTU and 3,500+ tickers.
Create a free account — keep ACTUGET /api/data?ticker=ACTU
This page as JSON via rel="alternate" · REST API docs · MCP server (51 tools) · llms.txt